Expression of adhesion molecules on acute leukemic blast cells and sensitivity to normal LAK activity
- 1 November 1993
- journal article
- Published by Springer Nature in Annals of Hematology
- Vol. 67 (5) , 213-216
- https://doi.org/10.1007/bf01715049
Abstract
Antigenic expression of CD54 and CD58 adhesion molecules was investigated on leukemic blast samples from ten patients with acute lymphoblastic (ALL) and 14 with acute myeloblastic (AML) leukemia. The mean intensity of fluorescence (MIF) was calculated and correlated with sensitivity of blast cells to the lytic activity of allogeneic lymphokine-activated killer (LAK) cells. CD54 antigen was expressed in all AML cases with an MIF of 11.2 while in ALL, though present in the majority of cases, it was absent in one case and expressed in less than 30% of blasts in two others, with an overall MIF of 3.0. CD58 expression was similar in both groups of patients, with an MIF of 7.6 in ALL and 7.0 in AML. In addition, in six of the ten ALL cases and in two of the 14 AML cases, leukemic blasts proved to be “resistant” to the cytotoxic activity of normal allogeneic LAK effectors. In these “LAK-resistant” patients, the CD54 antigenic expression was lower (p=0.03) than in “LAK-sensitive” patients with an MIF of 1.7 vs 4.9 in ALL and 1.35 vs 12.9 in AML cases. Finally, blocking of CD54 and/or CD58 receptors on leukemic blasts resulted in a slight reduction of51Cr release. Findings suggest that CD54 is differently expressed on myeloid and lymphoid blasts and that there is a correlation between CD54 MIF and susceptibility of blasts to the LAK activity.Keywords
This publication has 25 references indexed in Scilit:
- Resistance of leukemic blasts to lymphokine activated killer (LAK)-mediated cytotoxicity is not related to their adhesion propertiesEuropean Journal of Haematology, 2009
- A Supportive Role of Neurol Cell Adhesion Molecule (NCAM) in Adhesion Between Leukaemic Blasts and Cytotoxic LymphocytesScandinavian Journal of Immunology, 1992
- Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot studyBritish Journal of Haematology, 1991
- Adhesion characteristics of human interleukin 2-activated natural killer cellsCellular Immunology, 1991
- Interleukin 2 and the Treatment of Leukemia and LymphomaLeukemia & Lymphoma, 1991
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- The Lymphocyte Function Associated LFA-1, CD2, and LFA-3 Molecules: Cell Adhesion Receptors of the Immune SystemAnnual Review of Immunology, 1987
- Mechanism of Cytotoxicity by Natural Killer (NK) CellsAnnual Review of Immunology, 1986
- Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.The Journal of Experimental Medicine, 1983
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982